Nuvectis Pharma, Inc. NVCT EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvectis Pharma, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvectis Pharma, Inc.'s EPS (diluted)?
- Nuvectis Pharma, Inc. (NVCT) reported EPS (diluted) of -$0.26 in Q1 2026.
- How has Nuvectis Pharma, Inc.'s EPS (diluted) changed year-over-year?
- Nuvectis Pharma, Inc.'s EPS (diluted) increased by 3.7% year-over-year, from -$0.27 to -$0.26.
- What is the long-term trend for Nuvectis Pharma, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s EPS (diluted) has grown at a -18.1% compound annual growth rate (CAGR), from -$2.94 to -$1.32.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.